ASCO annual meeting featured a urothelial carcinoma session and a presentation by Dr. Shilpa Gupta discussing FGFR3 alteration status and outcomes with immune checkpoint inhibitors in patients with ...

New treatment combinations are transforming genitourinary cancer care, improving survival and quality of life while ...

Many men with aggressive prostate cancer can experience a high rate of recurrence despite treatment.A new Phase 2 clinical trial at UC Davis ...

(UroToday.com) The 2025 ASCO annual meeting featured a prostate cancer session and a presentation by Dr. April Rose discussing a ctDNA–directed phase II study of carboplatin in patients with ...

Oncology specialists from UC San Francisco will present new clinical research findings and cutting-edge treatment strategies at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, ...

While the medicine is free on the NHS in England for men with advanced prostate cancer, Giles has spent £20,000 on it. He ...

AI could eliminate the "postcode lottery" surrounding a life-extending treatment for advanced prostate cancer, researchers ...

Researchers used ArteraAI to identify 25% of prostate cancer patients in a large trial cohort for whom abiraterone halved the ...

At that point, additional blood and urine tests can spot biomarkers that may give a better indication if cancer is present, says Michael S. Leapman, M.D., a urologic oncologist at Yale Medicine. “They ...

The test, developed by Artera, uses AI to pick up features invisible to the human eye on images of tumour samples.

The FDA approved the poly ADP ribose polymerase (PARP) inhibitor in June 2023 in combination with enzalutamide for men with ...

Prostate cancer is the most common cancer affecting American men other than skin cancer and the second leading cause of male ...